Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2 Active not recruiting 22 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.

Timeline

Start: 2016-12-15
Primary completion: 2027-02-01
Completion: 2027-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribociclib	Small molecule	—	—

Indications

No indication recorded.